Back to discover
Drug

Clonidine

Established medicine
ClassAdrenergic receptor alpha-2 agonistResearchOngoing clinical research
Also known as Catapres, Chlorthalidone-Clonidine, Clorpres, Combipres+12 more

Catapres, Chlorthalidone-Clonidine, Clorpres, Combipres, Duraclon, Javadin, Kapvay, Nexiclon, Onyda, Clonidin, Clonidina, 2,6-Dichloro-N-2-imidazolidinylidenebenzenamine, 2-((2,6-Dichlorophenyl)imino)imidazolidine, CloNIDine HCl, CloNIDine Hydrochloride, Clonidinum.

9
Active clinical trials
3
Protein targets
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Consciousness and Psilocybin Effects on Well-Being: The CoPEWell Study

Clinical trial2026-07-02Results expected Q1 2028 · ClinicalTrials.gov

Adding Dexmedetomidine or Clonidine to Spinal Anesthesia for Cesarean Delivery

Clinical trial2026-05-05Results expected Q2 2028 · ClinicalTrials.gov

The PREVENT AGITATION Trial II - Children ≤1 Year

Clinical trial2026-01-31Primary completion · ClinicalTrials.gov

Treatment of Orthostatic Intolerance

Clinical trial2025-10-08Results expected Q4 2029 · ClinicalTrials.gov

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Clonidine
Aliases & brands
CatapresChlorthalidone-ClonidineClorpresCombipresDuraclonJavadinKapvayNexiclonOnydaClonidinClonidina2,6-Dichloro-N-2-imidazolidinylidenebenzenamine2-((2,6-Dichlorophenyl)imino)imidazolidineCloNIDine HClCloNIDine HydrochlorideClonidinum
RxNorm CUI
2599
ChEMBL ID
CHEMBL134
ATC codes
C02AC01N02CX02S01EA04
UNII
MN3L5RMN02
Primary mechanism
Adrenergic receptor alpha-2 agonist

Pharmacology & targets

3 targets

Known molecular targets and mechanisms supported by curated pharmacology databases.

AGONISTAdrenergic receptor alpha-2 agonist
AGONISTAdrenergic receptor alpha-2 agonist
AGONISTAdrenergic receptor alpha-2 agonist

Clinical trials

142 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
142
registered trials across all phases
LATEST COMPLETION 2026
9
Active studies
6
Recruiting
100
Late-stage (III+)
81
Completed
52
Discontinued
PHASE DISTRIBUTIONn = 142
Early Phase 12Phase 19Phase 1 / 28Phase 223Phase 2 / 36Phase 319Phase 447Phase N / A28

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • ClinicalTrials.gov — clinical trials